Literature DB >> 30502048

Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation.

Anat Berkovitch1, Arwa Younis1, Yoni Grossman1, Shlomo Segev2, Shaye Kivity3, Yechezkel Sidi4, Roy Beinart5, Ilan Goldenberg6, Elad Maor7.   

Abstract

Clinical and experimental data support a critical role for inflammation in cardiovascular disease. The purpose of the current study was to examine the relation between an inflammatory marker, neutrophil-to-lymphocyte ratio (NLR), and incident atrial fibrillation (AF) in asymptomatic adults. We investigated 21,118 self-referred men and women who were annually screened in a tertiary medical center. All subjects were free of AF at baseline and had their serum NLR calculated at the first annual visit. Subjects were divided into 2 groups based on their baseline NLR: Low (<2.83; n = 17,524) and high (≥2.83; n = 3,594; Upper Sextile). The primary endpoint was new onset AF during follow-up. Mean age of study population was 48 ± 10 years and 72% were men. A total of 563 (2.7%) incident events occurred during an average follow-up of 7.5 ± 5 years. Unadjusted Cox regression analysis demonstrated that each 1 unit increase in NLR was associated with a significant 14% increase in risk of occurrence of a first AF event (95% confidence interval 1.06 to 1.23, p < 0.001) and 20% increased risk of death. Kaplan-Meier's survival analysis showed that the cumulative probability of incident AF was significantly higher among subjects with high NLR compared with low NLR group (p = 0.006). Interaction analysis with adjustment to clinical parameters showed that NLR-related risk was age-dependent, such that in the younger age-group (< =50 years) high NLR group had two folds increased risk for AF event compared with low NLR group (95% confidence interval 1.08 to 3.51; p = 0.027) whereas among older subjects the rate of events was similar between both NLR groups (p = NS; p for interaction = 0.024). In conclusion, our findings suggest that high NLR is associated with increased risk of new onset AF. This finding is more pronounced among young adults.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30502048     DOI: 10.1016/j.amjcard.2018.10.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Association of RDW, NLR, and PLR with Atrial Fibrillation in Critical Care Patients: A Retrospective Study Based on Propensity Score Matching.

Authors:  Yao-Zong Guan; Rui-Xing Yin; Peng-Fei Zheng; Chun-Xiao Liu; Bi-Liu Wei; Guo-Xiong Deng
Journal:  Dis Markers       Date:  2022-05-27       Impact factor: 3.464

Review 2.  NETosis as a Pathogenic Factor for Heart Failure.

Authors:  Shuang Ling; Jin-Wen Xu
Journal:  Oxid Med Cell Longev       Date:  2021-02-23       Impact factor: 6.543

Review 3.  Inhibition of NETosis for treatment purposes: friend or foe?

Authors:  Tahmineh Mohammadi Chamardani; Samaneh Amiritavassoli
Journal:  Mol Cell Biochem       Date:  2022-01-07       Impact factor: 3.842

4.  The systemic-immune-inflammation index predicts the recurrence of atrial fibrillation after cryomaze concomitant with mitral valve surgery.

Authors:  Yu Luo; Jian Zhang; Tao Liu; Zongtao Yin; Yan Jin; Jinsong Han; Zhipeng Guo; Huishan Wang
Journal:  BMC Cardiovasc Disord       Date:  2022-02-13       Impact factor: 2.298

5.  Predicting Values of Neutrophil-to-Lymphocyte Ratio (NLR), High-Sensitivity C-Reactive Protein (hs-CRP), and Left Atrial Diameter (LAD) in Patients with Nonvalvular Atrial Fibrillation Recurrence After Radiofrequency Ablation.

Authors:  Bing Ding; Pengfei Liu; Fangfang Zhang; Jie Hui; Linyan He
Journal:  Med Sci Monit       Date:  2022-01-27

6.  Adenosine A2A Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients.

Authors:  Héctor Godoy-Marín; Romain Duroux; Kenneth A Jacobson; Concepció Soler; Hildegard Colino-Lage; Veronica Jiménez-Sábado; José Montiel; Leif Hove-Madsen; Francisco Ciruela
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.